Cargando…

Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease

Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Takuya, Ikemoto, Masaki, Matsuda, Shogo, Masutani, Ryota, Takeuchi, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456133/
https://www.ncbi.nlm.nih.gov/pubmed/36077067
http://dx.doi.org/10.3390/ijms23179669
_version_ 1784785737622749184
author Kotani, Takuya
Ikemoto, Masaki
Matsuda, Shogo
Masutani, Ryota
Takeuchi, Tohru
author_facet Kotani, Takuya
Ikemoto, Masaki
Matsuda, Shogo
Masutani, Ryota
Takeuchi, Tohru
author_sort Kotani, Takuya
collection PubMed
description Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of macrophages, on murine macrophage function and its therapeutic effect in a mouse model of bleomycin-induced ILD (BLM-ILD). To this end, the phenotype of thioglycolate-induced murine peritoneal macrophages co-cultured with hMIKO-1 was examined. The mice were assigned to normal, BLM-alone, or BLM + hMIKO-1 groups, and hMIKO-1 (0.1 mg/mouse) was administered intraperitoneally from day 0 to 14. The mice were sacrificed on day 28, and their lungs were evaluated by histological examination, collagen content, and gene expression levels. hMIKO-1 suppressed the polarization of murine macrophages to M2 predominance in vitro. The fibrosis score of lung pathology and lung collagen content of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. The expression levels of TNF-α, IL-6, IL-1β, F4/80, and TIMP-1 in the lungs of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. These findings indicate that hMIKO-1 reduces lung fibrosis and may be a future therapeutic candidate for ILD treatment.
format Online
Article
Text
id pubmed-9456133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94561332022-09-09 Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease Kotani, Takuya Ikemoto, Masaki Matsuda, Shogo Masutani, Ryota Takeuchi, Tohru Int J Mol Sci Article Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of macrophages, on murine macrophage function and its therapeutic effect in a mouse model of bleomycin-induced ILD (BLM-ILD). To this end, the phenotype of thioglycolate-induced murine peritoneal macrophages co-cultured with hMIKO-1 was examined. The mice were assigned to normal, BLM-alone, or BLM + hMIKO-1 groups, and hMIKO-1 (0.1 mg/mouse) was administered intraperitoneally from day 0 to 14. The mice were sacrificed on day 28, and their lungs were evaluated by histological examination, collagen content, and gene expression levels. hMIKO-1 suppressed the polarization of murine macrophages to M2 predominance in vitro. The fibrosis score of lung pathology and lung collagen content of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. The expression levels of TNF-α, IL-6, IL-1β, F4/80, and TIMP-1 in the lungs of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. These findings indicate that hMIKO-1 reduces lung fibrosis and may be a future therapeutic candidate for ILD treatment. MDPI 2022-08-26 /pmc/articles/PMC9456133/ /pubmed/36077067 http://dx.doi.org/10.3390/ijms23179669 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kotani, Takuya
Ikemoto, Masaki
Matsuda, Shogo
Masutani, Ryota
Takeuchi, Tohru
Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
title Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
title_full Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
title_fullStr Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
title_full_unstemmed Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
title_short Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
title_sort human miko-1, a hybrid protein that regulates macrophage function, suppresses lung fibrosis in a mouse model of bleomycin-induced interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456133/
https://www.ncbi.nlm.nih.gov/pubmed/36077067
http://dx.doi.org/10.3390/ijms23179669
work_keys_str_mv AT kotanitakuya humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease
AT ikemotomasaki humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease
AT matsudashogo humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease
AT masutaniryota humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease
AT takeuchitohru humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease